Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Further Allergy M&A On The Cards?

This article was originally published in Scrip

Executive Summary

Consolidation in the allergy therapy market looks set to continue following the recent merger of Stallergenes and Greer. Rumor has it that Germany's Merck may be about to sell its Allergopharma unit, which specializes in allergen immunotherapy, in which the cause rather than the symptoms of allergy are targeted.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register